-
Medicure International, Inc. v. Gland Pharma Ltd. DC
- 2:18-cv-16246
- D.N.J.
- Judge: Kevin McNulty +1
- Filed: 11/16/2018
- Closed: 08/22/2019
- Latest Docket Entry: 08/22/2019
- PACER
- Docket updated daily
1
Plaintiff
1
Defendant
1
Accused
Product
1
Patent-in-Suit
280
Days in
Litigation
-
Medicure International, Inc. v. Gland Pharma Ltd. DC
- 2:18-cv-16246
- D.N.J.
- Judge: Kevin McNulty +1
- Filed: 11/16/2018
- Closed: 08/22/2019
- Latest Docket Entry: 08/22/2019
- PACER
- Docket updated daily
Cause of Action
Willful Patent Infringement
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
Claim # | Claim Text | Outcome |
---|---|---|
1 |
A method for inhibiting platelet aggregation in a patient in need thereof, comprising 1) administering to the patient a bolus injection of an active drug, in an amount of about 25 μg/kg, and 2) administering to the patient, after the bolus injection,
view more
|
Enforceable and Valid
Entry 45 |
2 |
A method of claim 1, wherein the salt is tirofiban hydrochloride.
|
Enforceable and Valid
Entry 45 |
3 |
A method of claim 2, wherein the amount of tirofiban hydrochloride in the bolus injection is 25 μg/kg.
|
Enforceable and Valid
Entry 45 |
4 |
A method of claim 3 wherein the intravenous infusion is between 12 hours and 72 hours.
|
Enforceable and Valid
Entry 45 |
5 |
A method of claim 4 wherein the intravenous infusion is between 18 hours and 72 hours.
|
Enforceable and Valid
Entry 45 |
-
Infringement
Gland Pharma Ltd.
- 1 Detail
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
12.5 mg/250 ml (50 mcg/mL) tirofiban hydrochloride injection | US 6,770,660 B2 |
1, 2, 3, 4, 5
|
Infringement
Entry 45
|